UA71479A - Способ предупреждения ранних осложнений инфаркта миокарда с патологическим зубцом q - Google Patents
Способ предупреждения ранних осложнений инфаркта миокарда с патологическим зубцом q Download PDFInfo
- Publication number
- UA71479A UA71479A UA20031213242A UA20031213242A UA71479A UA 71479 A UA71479 A UA 71479A UA 20031213242 A UA20031213242 A UA 20031213242A UA 20031213242 A UA20031213242 A UA 20031213242A UA 71479 A UA71479 A UA 71479A
- Authority
- UA
- Ukraine
- Prior art keywords
- myocardial infarction
- therapeutically effective
- days
- wave
- day
- Prior art date
Links
- 208000010125 myocardial infarction Diseases 0.000 title claims abstract description 37
- 230000001575 pathological effect Effects 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 18
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229920000669 heparin Polymers 0.000 claims abstract description 25
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 11
- 230000001154 acute effect Effects 0.000 claims abstract description 11
- 229960002897 heparin Drugs 0.000 claims abstract description 11
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000001990 intravenous administration Methods 0.000 claims abstract description 4
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 10
- 229960003009 clopidogrel Drugs 0.000 claims description 9
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 9
- 229960000899 nadroparin Drugs 0.000 claims description 5
- 239000002175 thienopyridine Substances 0.000 claims description 5
- 229940125670 thienopyridine Drugs 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229950003543 nadroparin calcium Drugs 0.000 claims description 4
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 claims description 4
- 238000012876 topography Methods 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 description 13
- 239000003146 anticoagulant agent Substances 0.000 description 12
- 208000006011 Stroke Diseases 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 230000002537 thrombolytic effect Effects 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002785 anti-thrombosis Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000007211 cardiovascular event Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 206010002388 Angina unstable Diseases 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000007887 coronary angioplasty Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 201000005665 thrombophilia Diseases 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical class CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- NXXOEJWXTMWMHF-UHFFFAOYSA-N 5,6-didehydropyridine Chemical class C1=CN=C=C=C1 NXXOEJWXTMWMHF-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010049993 Cardiac death Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000288140 Gruiformes Species 0.000 description 1
- 206010020608 Hypercoagulation Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 241000838698 Togo Species 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229940095529 heparin calcium Drugs 0.000 description 1
- 230000003027 hypercoagulation Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002642 intravenous therapy Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229940020573 plavix Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Способ предупреждения ранних осложнений инфаркта миокарда с патологическим зубцом Q предусматривает пероральное применение аспирина и внутривенное применение нефракционированного гепарина в терапевтически эффективных количествах на протяжении острого периода инфаркта миокарда. Через 1-2 дня острого периода пациенту вместо нефракционированного гепарина вводят подкожно фракционированный гепарин в терапевтически эффективном количестве на протяжении, по крайней мере, 4-5 дней и дополнительно через 3 дня острого периода вводят перорально тиенопиридин в терапевтически эффективном количестве на протяжении, по крайней мере, 14-28 дней.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA20031213242A UA71479A (ru) | 2003-12-31 | 2003-12-31 | Способ предупреждения ранних осложнений инфаркта миокарда с патологическим зубцом q |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA20031213242A UA71479A (ru) | 2003-12-31 | 2003-12-31 | Способ предупреждения ранних осложнений инфаркта миокарда с патологическим зубцом q |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA71479A true UA71479A (ru) | 2004-11-15 |
Family
ID=74282703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20031213242A UA71479A (ru) | 2003-12-31 | 2003-12-31 | Способ предупреждения ранних осложнений инфаркта миокарда с патологическим зубцом q |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA71479A (ru) |
-
2003
- 2003-12-31 UA UA20031213242A patent/UA71479A/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | The clinical use of Fondaparinux: A synthetic heparin pentasaccharide | |
| Bhatt et al. | Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease | |
| Karjalainen et al. | A prospective randomised comparison of titanium-nitride-oxide-coated bioactive stents with everolimus-eluting stents in acute coronary syndrome: the BASE-ACS trial | |
| EA028885B1 (ru) | Способы лечения или предотвращения тромбоза стента и инфаркта миокарда (варианты) | |
| Elizari et al. | Morbidity and mortality following early administration of amiodarone in acute myocardial infarction | |
| Thomas et al. | Thrombotic stroke following snake bites by the “Fer-de-Lance” Bothrops lanceolatus in Martinique despite antivenom treatment: A report of three recent cases | |
| Franczyk-Skóra et al. | Acute coronary syndromes in patients with chronic kidney disease | |
| Hennekens et al. | Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions | |
| Lee et al. | Clinical safety of drug-eluting stents in the Korea acute myocardial infarction registry | |
| Rogers et al. | Current status of antithrombotic therapy in cardiovascular disease | |
| Dang et al. | Developments of anticoagulants and new agents with anti-coagulant effects in deep vein thrombosis | |
| Bauer | Fondaparinux: a new synthetic and selective inhibitor of Factor Xa | |
| Rizzi et al. | Treatment of arterial thrombosis in children: Methods and mechanisms | |
| UA71479A (ru) | Способ предупреждения ранних осложнений инфаркта миокарда с патологическим зубцом q | |
| Bergmann et al. | Uneventful removal of an epidural catheter guided by impedance aggregometry in a patient with recent coronary stenting and treated with clopidogrel and acetylsalicylic acid | |
| WO2012158003A1 (en) | Novel factor xii inhibitor | |
| Shafer | Cardiovascular chemotherapy: anticoagulants | |
| WO2003013423A2 (en) | Antithrombotic agent | |
| US6908907B2 (en) | Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients | |
| Van De Graaff et al. | Antiplatelet medications and their indications in preventing and treating coronary thrombosis | |
| Park et al. | C‐reactive protein as a cardiovascular risk factor and its therapeutic implications in end‐stage renal disease patients | |
| Muthu et al. | A rare manifestation of organophosphorus poisoning: hypothermia with cardiotoxicity | |
| Gasior et al. | Biodegradable polymer-coated thin strut sirolimus--eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population | |
| RU2649760C1 (ru) | Способ лечения острого инфаркта миокарда с подъемом сегмента ST, осложненного кардиогенным шоком | |
| Eagon et al. | Phosphanilic acid inhibits dihydropteroate synthase |